Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
Preclinical
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. is one of 31 therapeutic programs targeting Venous Thromboembolism. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
78 competitors in Venous Thromboembolism
#DrugCompanyPhaseTrials
1Pradaxa
Boehringer IngelheimPhase 3
Prilosec
DDexcel Pharma Technologies Ltd.
Phase 3
Fragmin
PfizerPhase 2
Low-Molecular-Weight Heparin
Daiichi SankyoPhase 3
Unfractionated Heparin
GSKPhase 3
REGN7508
RegeneronPhase 3
BAY 987519
BayerPhase 3
Dabigatran Dose 2
Boehringer IngelheimPhase 3
YM150
AstellasPhase 3
Du-176b
Daiichi SankyoPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- IInari Medical